Schedule 13G Filing by Integrated Core Strategies (US) LLC

Integrated Core Strategies (US) LLC, along with Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander, have jointly filed a Schedule 13G, indicating their beneficial ownership of AN2 Therapeutics, Inc. common stock. As of March 13, 2026, Integrated Core Strategies (US) LLC reported beneficial ownership of 2,135,044 shares, representing 6.0% of the class. This ownership is part of a larger holding by the Millennium entities and Israel A. Englander, who collectively beneficially own 2,237,102 shares, or 6.3% of the class. The filing clarifies that these securities were not acquired with the purpose or effect of changing the control of the issuer. The total number of outstanding shares considered for this filing is 35,647,635, which includes shares outstanding as of November 3, 2025, and shares issued in a private placement around March 10, 2026.